Briumvi
BRIUMVI (ublituximab-xiiy) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Click here to learn more.
What is Briumvi?
The most common adverse reactions (≥ 10%) were nausea, arthralgia, back pain, abdominal pain, and pyrexia. These adverse reactions, along with myalgia, musculoskeletal chest pain, and diarrhea may be signs and symptoms of an infusion-related reaction when observed during/within 24 hours of an infusion.
Possible Side Effects
Briumvi is the anti-CD20 therapy that is administered as a twice yearly 1 hour infusion (after 2 initial loading doses)
Administration Information
4 yearly treatments
What to Expect During Your Infusion:
Remember to drink plenty of water so you are hydrated for your appointment.
Your nurse will review your medical history, check your vitals, and discuss any questions and potential side effects of your infusion therapy.
Your nurse will begin your infusion and monitor you closely during your treatment.
You’ll continue to be monitored for 30 minutes post your infusion to ensure there are no reactions to the therapy.
IMPORTANT: Remember to let us know of any changes in your insurance prior to your visit to ensure that we are still an in-network provider for your infusion therapy.
Why Patients Choose Flourish for Infusion Treatments
At Flourish, our mission is providing patients with expert medical care and a relaxing spa-like infusion experience. Data suggests that care at ambulatory infusion centers costs over 50% less than the same services offered at hospitals. We also increase affordability with co-pay assistance and additional financial aid programs to our patients. Our clinical model ensures a 3:1 patient to nurse ratio. Popular entertainment streaming options, high speed WiFi access, relaxing recliners, and delicious food and beverage selections pamper patients and provide them with an experience they can enjoy for hours.